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ABSTRACT!
Cutaneous

infection of guinea

simplex-type 1 virus
model

(HSV-1)

pigs with herpes

provides an experimental

for the screening of potential

therapeutic agents
dideoxyuridine
potentially

in humans.

(AIU),

antiviral chemo¬

5-iodo-5'-amino-2’,5 * -

a novel

thymidine analog,

is a

important antiviral chemotherapeutic agent

which has been shown to

inhibit the replication of

herpes simplex-type 1 virus without causing any detectable
host toxicity

(1,

2,

3).

In contrast,

with demonstrated antiviral activity,
2’-deoxyuridine
(F3dThd),

(lUdR),

other nucleosides
such as

5-iodo-

5-trifluoromethyl-2'-deoxyuridine

1-beta-D-arabinofuranosylcytosine

and 9-beta-D-arabinofuranosyladenine

(Ara-C),

(Ara-A),

have

been shown to induce moderate to severe degrees of
cytotoxicity

(4,

5,

6,

In the following

7,

8).

study,

the efficacy of AIU in

the treatment of experimentally induced cutaneous
HSV-1

infection in guinea

with lUdR,

Ara-AMP

pigs was examined and compared

(adenine arabinoside monophosphate),

and lactose in a controlled,

double-masked experiment.

The results of this experiment
effectiveness of AIU in the treatment
HSV-1

demonstrated the
of cutaneous

infection in guinea pigs by a marked reduction in

1-
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the development of cutaneous erythema and the number of
vesicles at the HSV-1
the Ara-AMP and the
a

inoculated sites.

IUdR treated groups also exhibited

decrease in the severity of

the lesions as compared to

the lactose treated control group.
of these antiviral

In addition,

nucleosides,

The relative potency

defined in terms of

the reduction of cutaneous erythema and the number
of vesicles at
AIU,

IUdR,

the inoculated sites,

Ara-AMP,

in order of

ranked as

follows:

increasing potency.

The statistical analysis of

the experimental

data

documented the significance of the AIU treatment of
HSV-1 cutaneous lesions
mentioned criteria.

in the guinea

Similarly,

the

pigs by the above

IUdR and Ara-AMP treat¬

ments were also found to be statistically significant.
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5-IODO-5*-AMINO-2',5*-DIDEOXYURIDINE

(AIU)

OF CUTANEOUS HERPES SIMPLEX-TYPE 1

THERAPY

VIRUS

INFECTION IN GUINEA PIGS

I.

Structure and Composition of

the Herpes Simplex Virus

DNA core

The herpes simplex virus

(HSV)

virus composed of an inner core of
DNA with a molecular weight of
10,11).

The structure of

is a

relatively large

linear double-stranded

(99±5)

x 10

daltons

(9,

the DNA core has been studied

by electron microscopy,

which showed the HSV DNA to be

coiled in the form of a

doughnut

sition of
content,

the DNA,
is

The base compo¬

in terms of the guanine + cytosine

67 mole percent

percent for HSV-2

(12).

(10,

for HSV-1 and 69 mole

13).

Along the DNA strand,

there are alkali-labile bonds
of both HSV-1 and HSV-2

DNA

situated at unique sites
(10,

14)•

Further

tion regarding the DNA sequences of HSV-1

has

been obtained from the results of

3-

-

informa¬

and HSV-2

reassociation

'

kinetic studies of the DNA of HSV-1
from these studies

and HSV-2.

indicate that the HSV-1

likely contains no repetitive sequences
other hand,

16 percent

of the HSV-2

DNA most

(15).

On the

DNA sequences have

been found to reassociate more rapidly,
the theory that

The data

thus

repetitive sequences exist

supporting

in the HSV-2

DNA.
During the productive infection of
host cells,

it

is estimated that
17).

Hence,

the HSV within

50 percent
if

of the DNA

is transcribed

(16,

one assumes that

transcripts all

specify for the synthesis of

proteins,

then the HSV DNA must code the sequences of approximately
55,000 amino acids.

Capsid

The DNA core of the HSV is concentrically surrounded
by protein layers known as the capsid.
the HSV is composed of

162 structural

The capsid of
subunits called

capsomeres which form into an icosahedron
In addition,

the capsid of

(18,

the HSV is known to contain

spermine in amounts sufficient to neutralize
of the phosphate in the

19).

DNA

(20),

4-
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50

percent

Nucleocapsid

The unit containing the capsid and
nucleic acid is called the nucleocapsid,

its enclosed
which is a

rigid structure spanning approximately 95 to 105 nano¬
meters

in diameter

(11).

External

the capsid incorporates additional
the tegument.

to this structure,
proteins to form

The tegument has been found to bind

tenaciously to the capsid,
stripped the HSV of

even after detergents have

its outer envelope

(21).

Envelope

The nucleocapsid is coated by a loose envelope
which renders the virion
(22).
and at

This envelope
least

impermeable to negative stain

is composed of

12 glycoproteins

lipids,

(23,

20).

qualitative and quantitative differences

it

polyamines,
is the

in the glyco¬

proteins of the HSV envelope which determine the
immunologic

specificity of

the virus

(24) .

In addition to determining the immunologic
specificity,

the envelope also confers

to the nucleocapsid.

infectivity

It has been claimed that

naked nucleocapsid does not absorb well

to cell

the
surfaces

and is less stable than the enveloped nucleocapsid.

5-
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Obtained from either the nuclei

or the virion

exposed

to lipases or lipid solvents which strip the envelope
off the nucleocapsid,

the

resulting naked nucleocapsid

are found to be noninfectious.

However,

an

intact

envelope may not be required for infectivity,
fragments of

since

the envelope adhering to the nucleocapsid

are sufficient

to render it

proteinized HSV-1
also infectious

DNA,
(27),

infectious

(25,

26),

De-

either native or denatured,
Even portions of

is

the HSV DMA

0
from a deletion mutant

lacking 4 x 10

daltons

in

its

(28).

DMA has been reported to be capable of multiplying

Cellular HSV

Infection

Cellular infection by HSV can lead to either
(1)

productive

infectious
or

(2)

infection

progeny and subsequent cell

nonproductive

the viral genome
ing cell

in which biosynthesis of

death

infection

in which part or all

of

resides within the host without caus¬
(29,

30),

Productive infection of

HSV leads to multiplication of
host tissue destruction,
tion clinically.

death take place

infectious virus

and manifestation of

But nonproductive infection

the

progeny,

the

infec¬

is believed

to be responsible for recurrent HSV infection and cancer.

6-
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Productive infection and replication of HSV

Productive infection
with the initiation of
The mechanism of

HSV is unknown;

One method of entry is believed to

the host cell

involve

envelope with the plasma mem¬
(31),

while the other method

is believed to be akin to pinocytosis
The entry of virus

into cells

is

(32).
influenced by

the temperature and the extracellular medium.
known that polyanionic substances

It

is

such as heparin and

dextran sulfate inhibit HSV infection of cells
although HSV-1

however,

entry into the host cells have been

the fusion of the viral
brane of

begins

infection within the host.

penetration of

two modes of viral
• postulated.

in the host cell

(33),

is less susceptible to the effects of

polyanionic extracellular medium than is HSV-2

(34).

It has been postulated that polyanions may compete with
HSV for the attachment to the receptors on the cell
surface,

thus hindering the HSV attachment and entry

into the cell
The cell

(35).
to cell transmission of HSV infection

may occur in the absence of
particles

(36).

detectable infectious

The transmission is achieved by the

fusion of the HSV infected cells with the adjacent

7-
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uninfected cells

(37).

After the entry of the virus into

the cell, the outer protein capsid is stripped,

resulting

in a DNA-protein complex which enters the nucleus.

Within

the nucleus, the DNA becomes dissociated from the protein,
and the viral DNA is transcribed.

Forty-four percent of

the HSV-1 DNA and twenty-one percent of the HSV-2 DNA is
transcribed prior to the onset of DNA synthesis.

The

transcription of the viral DNA sequences is regulated such
that some transcripts are more abundant than others

(16, 17).

The virus specified RNA is then processed and transported
into the cytoplasm where it directs the synthesis of
structural and nonstructural proteins of the virus at the
free and membrane-bound polyribosomes

(38,

39, 40, 41).

These newly synthesized proteins specified by the HSV then
migrate to the nucleus. However, a small portion of these
proteins remains in the cytoplasm and binds to the cellular
membranes

(41).

The structural proteins are assumed to regulate the
synthesis of HSV DNA.

The virus specified enzymes have

been identified as thymidine kinase and DNA polymerase.
The HSV specified thymidine kinase differs from the
host thymidine kinase in its immunologic, electrophoretic,
physical, and catalytic activity since HSV-thymidine kinase also
phosphorylates deoxycytidine.

8-

Differences in these

/

properties have also been shown to exist between the HSV-1
specified thymidine kinase and the HSV-2
thymidine kinase

specified

(42) .

The synthesis of herpes virus nucleic acid occurs
within the Feulgen-positive Cowdry Type A inclusion body
found in the nucleus
along several

(41).

sites of

The DNA synthesis is

the molecule

(14).

initiated

The newly

synthesized DNA fragments are not processed beyond
the
viral

interruptions found at the unique sites.

The

DNA within the intranuclear space has greater

number of alkali-labile bonds than those found in the
nucleocapsid

(14).

The structural

proteins of

the nucleus to form the capsid

the virus migrate into
(41).

Three types of

capsids have been identified from electron microscopic
studies.

They are as

core,

capsids with DNA core,

(2)

follows:

(1)

capsids without

and

(3)

capsids with

tegument adhering to the nuclear membrane.
the capsids without

DNA cores

DNA

However,

rarely have envelopes

surrounding the naked capsid in the HSV-infected cells
(43).

In addition,

the protein compositions of

types of capsids also differ from each other

the three
(21,

43,

44).
The nucleocapsids become enveloped at the inner

9-
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lamella of the nuclear membrane at a region of de novo
synthesis of nuclear membrane or at a site at which host
proteins have been expelled (23, 43, 44).

The inner lamella

at the site of envelopment thickens due to the acquisition
of a layer of protein to form the tegument.
The enveloped virus is sequestered between the inner
and the outer lamellae of the nuclear membrane and within
the endoplasmic reticulum.

The HSV is protected from any

direct contact with the cytoplasm.

The mode of egress

of the HSV from the infected cell is not entirely clear.
One theory states that the endoplasmic reticulum contain¬
ing the HSV forms vesicles which transport the HSV to
the extracellular fluid (45).

A second theory states that

the endoplasmic reticulum connects the extracellular fluid
with the perinuclear space containing the HSV and thus
provides a pathway for the HSV to migrate from the infected
cell

(46).

Cellular changes due to the HSV productive infection

Productive infection of HSV drastically alters
the infected cell’s DNA,
47, 48).

protein, and RNA synthesis

(41,

Inhibition of host DNA and protein synthesis

begins with the entry of HSV into the cell and is
complete within three to five hours.

10-
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The inhibition of

DMA and protein synthesis

is accompanied by the displace¬

ment of aggregates of chromatin at

the nuclear membrane

and the disaggregation of polyribosomes.
thesis

Host RNA syn¬

is altered by the productive infection of HSV.

Ribosomal

precursor RNA is

The host RNA is

decreased up to 70

improperly processed,

the degradation of methylated 45S
than the normal cleavage

percent.

resulting

in

ribosomal RNA rather

into 18S and

28S segments.

The remaining RNA which is processed does not enter
the polyribosomal
thesis

pool

to regulate host protein syn¬

(47).
Other effects of productive infection by the HSV

is manifested by the leakage of macromolecules
the

infected cell

(49,

50)

transmembrane potential
infected cell

and the reversal

from

of the

from -20 mV to +10 mV in the

(51).

The HSV infected cells acquired new surface
immunologic

determinants which are similar to those on

the surface of the envelope of
54,

55,

56,

57),

the virus

These infected cells

or may fuse together,

thus creating a

(42,

52,

53,

form loose aggregates
direct cell-to-

cell contact which may faciliate the dissemination of
the HSV infection

(58,

59),

11-
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Recurrent HSV Infection

A characteristic of HSV infection in humans, as
well

as nonhuman species

the host,

is

its ability to persist

leading to recurrent

infections

specific area of the host's body,
face,

or genitals

causing recurrent
apparent,

(29,

30,

60).

infections

localized on

such as

the cornea,

The origin of the virus

in the host

is not usually

although four theories have been stated to

explain these recurrences.
(1)

exogenous

infection}

another site of

They are as follows:

(2)

the body;

endogenous

(3)

chronic,

infection

from

continuous

low-

level viral multiplication near the site of
(4)

persistence of the virus

at or near the site of

involvement;

in a non-replicating form

recurrent

infection.

The data which supports the exogenous
theory is based on occurrences of genital
with exogenous HSV-2
In humans,

in

it

reinfection

reinfection

in mice and Celius monkey

(6l) .

is unlikely that exogenous source of virus

is responsible for the recurrences of nongenital
infection since these

HSV

recurrences correlate to such

precipating factors as exposure to sunlight,

fever,

menstruation,

(60,

hormones,

or emotional

stress

29,

30) .
The theory of endogenous reinfection

12-
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from another

site of the body is also unlikely to be the primary
cause responsible for recurrent

infections,

even

though such instances have been documented

in

of genitals with HSV from a

infection

(62).
a

recurrent oral

This theory cannot account

specific

region of

the body is

for the fact
involved

infections

that only

in recurrent

infections.
The most convincing evidence against
of chronic,

continuous low-level viral multiplication

around the site of

involvement

numerous attempts to

is

the

isolate virus

taken from the site of

recurrences

between recrudescences

(29,

30,

failures of

from biopsy specimens
in the

in its non-

infectious state at or near the site of
supported by findings

interim

60).

The theory that the HSV persists

recurrence is

in both animals and humans.

HSV have been cultured from the trigeminal
from human cadavers

(63,

64).

In animal

mice and in the trigeminal ganglion of

(65,

in the foot

13-
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HSV

ganglion of

rabbits after

pad and the cornea

66).

ganglion

studies,

have been found in the sacrosciatic spinal

inoculation

the theory

respectively

II.

The Epidemiologic

of Herpes Simplex Virus

Patterns
Infections

The discovery of two natural variants of
(type 1

and type 2)

have made the epidemiologic pat¬

terns of HSV infections more meaningful.
epidemiologic studies
antibodies

(Abs)

HSV

From the

based on the detection of HSV

in the general

population,

evident that the acquisition of HSV Abs

it is

is markedly

influenced by an individual's age and socioeconomic
status.

The incidence of

finding

HSV-1 Abs

directly with an individual's age,

increases

beginning after

six months of age when the transplacental Abs

from

the mother disappear from the newborn’s immunologic
defense system.
HSV-1 Abs is
status.

On the other hand,

inversely related to one’s socioeconomic

For example,

economic group have a
HSV-1 Abs,

the adults
30

in the higher socio¬

to 50 percent chance of having

while the adults

group have an 80 to 100
Abs.

the presence of

in the lower socioeconomic

percent chance of having HSV-1

Similar trends exist for the incidence of HSV-2

14-
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Abs

in the general

by the sexual

population,

is

found beginning at 14 years

The incidence of HSV-2 Abs

population is 10 percent
group,

is modified

behavior within each population subgroup.

A rise of the HSV-2 Abs
of age.

although it

in the higher socioeconomic

between 20 to 60 percent

economic group,

3

in the lower socio¬

percent in nuns,

in prostitutes -(67,

in the adult

and 100

percent

68).

HSV is commonly transmitted by direct contact
such as

in the cases of herpes gladiatorum

The transmission of HSV-1

is

(69,

predominately via

70,

71),

the

oral-respiratory route with contaminated secretions
from host to host.
saliva

The transmission of the virus

the

is exemplified by the increased incidence of

herpetic paronychia

in medical and dental

personnels

exposed to patients with infected oral cavity or con¬
taminated tracheal
HSV-2

catheters

(72,

73,

74).

is generally transmitted via contaminated

genital secretions of symptomatic and even
persons

infected with HSV-2.

source of HSV is

In the newborn,

from the mother who

genital HSV-2 or less
The transmission of

asymptomatic

is

frequently HSV-1

infected with
(75,

76,

77,

78),

the virus occurs during the passage

of the fetus through the infected birth canal
percent of

the major

such cases

(77).

15-
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in

50

.

III.

Clinicopathologic Aspects of HSV Infections

The incubation period for primary HSV-1 or HSV-2
varies from 2 to 20 days,

with an average of

In patients with primary HSV infections,

then

days.

the HSV Abs

can be detected within the first two weeks
serum fraction,

6

in the

IgM

followed by detection in the

IgA

and IgG fractions afterwards

(79).

Delayed hyper¬

sensitivity reaction to HSV antigens as exhibited by
a

positive skin test usually develops

Dissemination of

(80,

81).

Primary HSV Infection

The dissemination of

primary HSV infection generally

occurs only in the compromised host.

The pathologic

process of HSV dissemination have been described as
follows

(75,

82),

Initally,

primary viremia

results

from a spillover of the HSV from the infected cells
located at the portal of entry.
spread of HSV infection
At this

point,

This

leads

to the

to the susceptible organs.

histopathogic changes remain minimal

16-
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in the

infected organs.

the infection,
that virus

In the progressive phase of

the viremia disappears at the same time

replicates within the target organs.

leads to the cellular damage in these tissues.
ing this

phase,

a secondary viremia

develops

This
Follow¬

from the

production of virus within the target organs.

The

secondary viremia leads to further spread of virus to
involve other organ systems.
the regression and the

This

phase is

followed by

recovery of

the host

from the

HSV dissemination.

HSV Infection

in the Noncompromised Host

HSV viremia

is

rarely encountered in the non¬

compromised host who is greater than one month of age
(83,

84,

85).

In this type of hosts,

KSV infection is

generally localized in specific target organs without
the development of
organs

systemic dissemination.

The target

infected by the HSV are derived from the embryonic

ectoderm such as

the skin,

oral

cavity,

vagina,

conjunctiva,

and nervous system.
The factor which determines whether HSV-1
HSV-2

is

or

involved in the infection of a specific organ

ls the mode by which the virus gains entry into the host.
However,

one cannot totally disregard the general

perties of each virus type in

determining the tissue

17-
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pro¬

susceptibility or the route of

dissemination within

the host.

HSV Infection of

the Oral-respiratory Tract

Oral herpetic

infections are generally caused

by HSV-type 1,rather than HSV type
the mouth is

2.

In children,

the major site of primary HSV-1

The clinical manifestation of

the HSV infection of

mouth in the noncompromised host varies
subclinical

infection.
the

from inapparent,

infection to severe gingivostomatitis with

vesicular lesions and ulcers of

the mucous membrane,

cervical

(86),

adenopathy,

and fever

contact transmission of

Further direct

the contaminated secretions

can lead to subsequent infection of other susceptible
organs such as the eye,
the other hand,

genitalia,

primary HSV-1

fingers,

infection of

etc.

On

the mouth in

neonates or in the compromised host can extend to the
lungs and the esophagus with a potential
tion to other visceral
system

(75,

87,

HSV Infection of

88,

for dissemina¬

organs or the central nervous

89).

the Lios

Primary HSV infection involving the lips
common,

but it

is not

is the site most commonly involved in

18-
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recurrent
in

HSV lesions.

labial herpes

lip cancer
5

The site of

is well

the lips

involved

corrolated with the site of

(90). Labial herpes generally heals within

to 7 days without the development of extensive com¬

plications except

in those instances

involving the

compromised hosts of Hodgkin patients
these patients,
of

there

92) . In

is a tendency for the persistence

the lesions or the extension of

HSV Infections of

(91,

the

infection locally.

the Eves

HSV infection of

the eyes

primary or recurrent disease,

is

due to HSV-1

except

in

in the newborns

when HSV ocular lesions are often due to HSV type
The severity of

the

infection

is

2.

dependent on the

depth of the lesion and the recurrent nature of the
tious process.
includes

The spectrum of such ocular

follicular conjuctivitis,

stromal keratitis,
uveitis

(93,

94,

ocular infections,

can

cataracts,
95,

96).

involvement

superficial

iridocyclitis,

or

and pan¬

With severe and recurrent HSV

the tissue damaged from the infection

markedly impair the vision of

the afflicted in¬

dividual .

HSV Infections of

infec¬

the Skin

HSV infections of the skin generally occur in

19-
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a

diseased,

broken,

an intact skin.

or traumatized skin,

but not

in

The skin lesions which develop from

primary or recurrent HSV are localized vesicular lesions.
The course of

these skin Vesicular lesions

is

influenced

by the immunologic status of the afflicted individuals
In the compromised host,

these skin lesions

extensive and chronic in nature

(91,

92).

become more
In those

individuals having atopic eczema or dermatoses such as
Darier's

disease,

the HSV vesicular lesions become more

generalized to form Kaposi’s varicelliform eruption or
eczema herpeticum
in such cases,

(97).

Recurrences have been described

although they are usually less

and shorter in duration than the initial
In traumatic herpes
via a

lesion,

break in the epithelium of

abrasion,

laceration,

severe

primary infection.

the HSV enters
the

the skin

skin from an

puncture or burn wound.

Such skin

lesions often occur in the fingers as herpetic whitlow
in wrestlers as herpetic gladiatorum

(71,

72),

and in

burn patients who are more susceptible to systemic
herpetic

infections

(88).

Neonatal herpes can present with skin vesicles,
although the skin lesions are sometimes absent
Occasionally,
precedes

(75),

a generalized macular erythematous

the onset of the vesicular lesions.

infected neonate survives the initial
these lesions can

20-

the

HSV infection,

recur at the original

-

If

rash

sites,

as well

(72),

as new locations.
HSV infections of
type 1 or type 2,
of the virus.
to HSV-2;

the skin can be due to either

depending on the mode of acquisition

Hence,

neonatal herpes

skin lesions

in adults

is often due to HSV-1;
the waist of adults

HSV Infections of

disease,

located above the waist

and those lesions

located below

is often due to HSV-2.

the Urogenital

HSV infection of
venereal

is generally due

Tract

the urogenital

tract

is a common

predominately due to HSV-2.

Only 5

to 10 percent of HSV infections of the urogenital
are due to HSV-1.

HSV-1 urogenital

are mainly due to autoinfection
the body,

as

urogenital

seen in those cases

tract

In females,

tract

tract

infections

from another site of
involving HSV-1

infection in children

(62),

the HSV infection occurs more com¬

monly in the cervix than in the external genitalia
(71,

72,

males,

73),In the symptomatic or the asymptomatic

the virus have been

urethra,

isolated from the penis,

prostate and the seminal vesicles.

The clinical manifestations of HSV genital
fection is

in¬

dependent on the presence of neutralizing

Abs to either types of
neutralizing Ab to HSV,

HSV.

In the absence of any

the clinical manifestations of

21-
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genital

HSV infections

tend to be more severe.

It

may be complicated by such symptoms and signs as
constitutional
In addition,

signs,

reginal adenopathy and dysuria.

genital herpetic

infections can be accompanied

by pleocytosis of the cerebrospinal
absence of meningeal

fever,

sings,

fluid,

radiculitis,

even in the

or myelitis

(83) .

HSV Infection of

the Nervous System

HSV infection of
as encephalitis,
(83,

98,

99).

the nervous system can manifest

meningitis,

radiculitis,

HSV infection of

or myelitis

the nervous system may

be due to a primary infection limited to the brain,
it may occur in disseminated HSV infections,
in the cases

indicate that the mode of

HSV may differ according
HSV-2

particularly

involving newborns.

Studies

(83).

or

is

spread of

the

to the type of HSV involved

thought to spread to the nervous tissue

via the hematogenous pathway,
to spread to the nervous

while HSV-1

is

thought

tissue predominately via

the

neurogenic pathways.
The type of
tissues

HSV causing the

infection of nervous

is dependent upon the age of the host.

for newborns,

Except

these infections are commonly due to HSV-1.
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IV.

The Treatment of HSV Infections

At the present time,

there are several

approaches

available experimentally and some available clinically
for the treatment of HSV infection

in humans.

Anti¬

metabolites composed of nucleoside analogues have
varying degrees of effectiveness against HSV infection.
Photodynamic
as neutral

inactivation using heterotricyclic

red or proflavine is under investigation

the treatment of HSV infection.
as BCG,

dyes

smallpox vaccines,

such
for

Immunizing agents such

and most

recently, inactivated

HSV vaccines have been examined in this country as well
as

in Germany and in France.

Interferon and interferon

inducers are also under investigation for the therapy of
HSV infections.

Nucleoside Analogs

5-Iodo-2 *-deoxvuridine

5-Iodo-2'-deoxyuridine

(IUdR),

23-
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a synthetic nucleoside

analogue discovered in 1959

was

the

first agent used clinically for the treatment of

HSV

infection

the corneal

103,

104,

the topical

HSV infection

IUdR for the treatment of

epithelium in rabbits and in humans

has been demonstrated by several
102,

Prusoff,

(100). The effectiveness of

administration of
of

by W.H.

investigators

105). Unfortunately,

IUdR has

(101,

proved to

be ineffective for the treatment of herpes

labialis

a

(106).

double-masked study by Kibrick and Katz

In addition,

IUdR has limited application for the

management of cutaneous and genital herpetic
due to the lack of
on the host

(98,

its

of

therapeutic response and the toxicity

activity of

incorporation

stitution for the

infections

107).

The antiviral
result of

in

IUdR is believed to be the

into the viral

thymidine moiety.

DMA,

in sub¬

The incorporation

IUdR into the DMA of animal viruses have been estab¬

lished by several
112).

investigators

(49,

108,

109,

110,

111,

The incorporation of halogenated deoxyribonucleosides

have been shown to inhibit the formation of
.
herpesvirus particles to a

to one infectious virus

7
ratio of 10

(113,

resulting

the herpes virus

from the

virus particles

114),

The specific molecular defect
changes

infectious

responsible for these

incorporation of

IUdR into

DMA has not been elucidated,

24-
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but

Prusoff

and Goz have reviewed this subject extensively

(115,

116).
The use of topical

or systemic

IUdR is associated

with considerable toxic side effects.
most likely a consequence of

the

The toxicity is

incorporation of

into the DNA of normal uninfected host cells.
systemic administration of
centration of
effects
(117),
of

100

IUdR in patients at a con¬

reported are stomatitis,

patients,

leukopenia,

administration of

and alopecia

IUdR in the eyes

follicular conjunctivitis,

narrowing and occlusion of the puncta,
lid margin changes and excess
(118).

have been

the toxic

ocular toxic effects such as punctate

epithelial keratopathy,

ported

In the

mg/kg/day for 5 to 6 days,

In the topical

IUdR

contact dermatitis^

lacrimation have been re¬

During corneal wound healing,

toxic changes

observed in the regenerating epithelium(119,

and the stromal

regeneration of the cornea

In experimental models,
with teratogenic changes

(119,

121)

120)
.

IUdR hav been associated

in laboratory animals.

These

teratogenic changes have been demonstrated in pregnant
rabbits treated with topical administration of

IUdR

to the eyes at doses comparable to that used in humans
(122).

Subcutaneously injected IUdR has also been shown

to induce teratogenic abnormalities
and mice,

consisting of changes

25-
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in neonatal

rats

in the granular and

molecular layers of
nephrogenesis,

the external

ocular abnormalities

subcapsular cataract,
retinal

dysplasia

(123,

posterior
and

124),
lUdR is

further limited by the

lUdR resistant strains of HSV

The primary use of
Keratitis,

such as

impaired

retarded retinal maturation,

The clinical use of
existence of

cerebellum,

lUdR has been

(125,

126) ,

in herpes simplex

using either ophthalmic ointment at 0,5%

or ophthalmic solution at 0.1% concentration.

9-Beta-D-arabinofuranosy1adenine

9-Beta-D-arabinofuranosyladenine

(Ara-A)

was

orignially synthesized in 1960 as an anti-cancer agent
(127),

Ara-A has antiviral

activity against a broad

\

spectrum of
some of

DNA viruses

the of

including the HSV,

as well as

the oncogenic RNA viruses such as the

Rous Sarcoma virus and the Gross murine leukemia virus
(128,

129,

130,

131) ,

The current clinical usefulness of Ara-A is pre¬
dominately in the treatment of ocular HSV infections.
It is equally as effective as

lUdR in the therapy of

acute primary or recurrent dendritic keratitis caused
by HSV,

In addition,

Ara-A can be used to treat those

diseases caused by lUdR resistant strains of HSV
132,

133,

134,

135,

136,

137) .
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(119,

The intravenous administration of Ara-A has been
successfully used

in the treatment

herpes kerato-uveitis

(138).

of

Ara-A may be beneficial

in the treatment of neonatal herpes
early in the course of

the

patients with

if administered

infection

(139).

However,

the response of genital herpes simplex infection to
Ara-A has been highly variable
been tested in a
encephalitis
show a
percent

(140).

Ara-A has also

placebo-controlled study on HSV-1

in humans.

reduction of

The results

from this

study

the mortality rate from 70 to 28

in patients with HSV-1 encephalitis when they

were treated with Ara-A early in the course of the
infection

(141).

The mechanism of action of Ara-A has not been
completely elucidated.

The antiviral

activity of Ara-A

may be attributed to the

incorporation into the DMA

and/or the inhibition of

DMA polymerase

The deaminated product of Ara-A,
derivative of Ara-A,

(142,

the hypoxanthine

is approximately equal

in its antiviral activity

143).

to Ara-A

(129),

The administration of Ara-A has been associated
with the following toxic effects.

In the systemic

administration of Ara-A to patients with chronic
hematologic conditions,

a mild to moderate depression

in the level of the hemoglobin was observed,
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without

any accompanying change in the neutrophils and platelet
levels

(144).

Two patients with Hodgkin's

receiving Ara-A at

20 mg/kg/day have been reported to

develop a transient motor aphasia
mutism

(144).

disease

resembling akinetic

Chromosomal gaps and breaks have been

observed in leukocytes treated with in vitro Ara-A
(145),

Systemic administration of Ara-A in patients

have also been associated with an

increase in chromo¬

somal breakage found in the leukocytes
its toxicity,

(146)*

Besides

the therapeutic usefulness of Ara-A is

also limited by its low water solubiltiy.

9-Beta-D-Arabinofuranosvladenine-5 *-Monophosphate

9r-Beta-D-Arabinofuranosyladenine-5' -monophosphate,
i

or Ara-AKP,

is a modified compound of Ara-A by the

addition of a

phosphate group.

over Ara-A is

the

Its major advantage

increased water solubility property,

as compared to its parent compound Ara-A

(147).

Ara-

\

AMF has been shown to have marked in vitro and
activity against a host of

DNA viruses

(148,

in vivo
149) .

Other studies have demonstrated its effectiveness
the treatment of HSV-1 keratitis
and in herpes virus
of mice

in rabbits

induced cutaneous lesions

(148) #
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(148,

in
150)

in tails

,

■

Preliminary toxicity studies have not shown AraAMP to be more toxic than Ara-A

(151).

solubility in water,

be a

Ara-AMF can

Because of

its greater

potentially impor¬

tant antiviral agent that can be administered via paren¬
teral

routes

in smaller fluid loads than Ara-A.

ever,

further toxicity studies are needed prior to the

initiation of clinical

How¬

trials of Ara-AMP.

1-Beta-D-Arabinofuranosvl

1-Beta-D-Arabinofuranosyl

Cvtosine

cytosine

(Ara-C),

originally developed as an antileukemic agent,

has a

spectrum of antiviral activity similar to Ara-A.
antiviral

potential of Ara-C has

(4,

152,

7,

8,

153).

s

It has

The

been reviewed extensively

been established that Ara-C

is active against experimental herpetic and vaccinia
keratitis.

However,

the clinical use of Ara-C in the

treatment of herpetic keratitis
due to Its toxicity.

Similarly,

in humans

is

restricted,

systemic use of Ara-C

for the treatment of other herpes simplex infections are
also restricted.
unity for Ara-C,
(154),

The therapeutic to toxic ratio approaches
being 10 times more toxic than

IUdR

The systemic toxicities of Ara-C include terato-

genesis,

immunosuppression,

leukopenia,

chromosomal

thrombocytopenia,

aberration,

megaloblastosis,
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hepatic

toxicity,

and gastrointestinal

Reports of

toxic changes

Ara-C in the eyes
pathy,

and iritis

its toxicity,

Ara-C’s clinical

further * limited by its

inactive metabolite of Ara-C.

rapid deaminiation
arabinoside,

However,

an

the deamination

is less of a concern in intrathecal administra¬

tions of Ara-C since deaminases are absent
Thus,

157).

(158).

in the liver and the kidneys to uracil

of Ara-C

156,

include punctate epithelial kerato¬

In addition to
is

(155,

following the topical use of

corneal ulceration,

usefulness

toxicity

the active form of Ara-C will

when intrathecal

in the brain.

persist much longer

injections are given

(159).

5-Trifuoromethyl-2 *-Deoxvuridine

5-Trifluoromethyl-2*-deoxyuridine

(F3TdR)

is an

antineoplastic agent which is highly active against
HSV

(160).

In contrast to

the potency of

IUdR,

FgTdR has been reported to be 10-fold

greater than that of

IUdR in the treatment of herpetic

keratitis in rabbits.
herpetic keratitis,

In clinical

trials of

in which 1% solution of

tested against 0.1% solution of
be more effective than

IUdR

Ara-A in the treatment of
humans,

the solubility and

IUdR,

F3TdR on
F-^TdR was

F^TdR proved to

(161). When compared to

dendritic keratitis

there was no statistical
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in

difference between

the use of FgTdR and Ara-A (162).
From the extensive studies performed primarily
with vaccinia virus,

the

mechanism of antiviral action

of FgTdR is believed to be due to its incorporation
into the virus DNA (163, 164) and its subsequent
alteration in the transcription of late mRNA (165).
In experimental models, bone marrow toxicity and
teratogenic activity have been reported with the use
of F^TdR (168,

169).

F^TdR has been found to be

mutagenic to bacteriophage

but not mutagenic to

Chinese hamster cells in culture (3).

F^TdR therapy

of herpetic keratitis has produced punctate

epithelial

erosions and epithelial microcysts when administered
more frequently than 5 times daily for more than a few
days.

Further application of F3TdR at this point has

produced frank epithelial edema with stromal swelling
(118).

When used topically in the eyes of rabbits,

F^TdR has not produced teratogenic changes, unlike
the teratogenic changes reported with topical use of
IUdR (122).
FgTdR, as with IUdR,

is incorporated into the

viral DNA and the uninfected host cell DNA (164).
The toxicity of F^TdR is thought to be related to
its incorporation into the DNA of the uninfected host
cell and the irreversible inhibition of thymidylate

-31-

synthetase,
dTMP,

an

enzyme needed in the biosynthesis of

an essential

precursor of

DNA

(166,

167),

5-Trif luoromethyl-5 * -Amino-2 * , 5 * -Dideoxyuridir.e

An analog of

F^TdR is

2 *,5 *-dideoxyuridine,
Chai,

and Irusoff

fold less

5-trifluoromethvl-51-amino-

which was

in 1976

synthesized by Lin,

(170),

potent as an antiviral

Although it

is

four¬

agent against KSV in

Vero cells than its parent nucleoside,

F^TdR,

40 times less

the therapeutic

index of

toxic

than F^TdR.

F^TdR has been

Thus,

improved by a

it

factor of

is also

10 when

modified to its 5 *-amino analog.

5-Iodo-2'-Deoxycytidine
V

5-Iodo-2'-deoxycytidine or
analog of
(171),

lUdR which was

Studies

IdCyd is

a precursor

initially synthesized in 1961

performed on IdCyd demonstrated its

effectiveness against HSV in culture

(172)

herpetic keratitis

It

in rabbits

(173).

and in

is known that

IdCyd and its bromo analog not only inhibit HSV in culture,
but they are also substantially less toxic to the un¬
infected host cell

than their deoxyuridine analog

The selective action of

IdCyd on the virus

(174),

infected

cells is dependent on its phosphorylation by only the

32-
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virus induced deoxycytidine kinase.

This property may

also explain why IdCyd is more effective than IUdR
in the treatment of experimental deep herpetic keratitis
(175).

IdCyd is not converted into its active deaminated

derivative until it is within the virus infected cells
and has been phosphorylated by the virus induced deoxy¬
cytidine kinase.

Therefore,

in deep herpetic keratitis,

IdCyd is protected from being metabolized on the surface
until it reaches the

deep layers of the infected cells.

On the other hand, the clinical efficacy of IdCyd is de¬
pendent on the quantity of deoxycytidine kinase within
the virus infected cells.

Although several investigators

have found an increase in the quantity of deoxycytidine
kinase in the HSV infected cells

(176, 177), a contradictory

report has shown no increase of deoxycytidine kinase in
the HSV infected cells (178).

In the latter case,

IdCyd is totally ineffective as an antiviral agent.

5-Ethvl-2 *-Deoxvuridine

The synthesis of 5-ethyl-2*-deoxyuridine was
reported in 1969

(179, 180).

It is an inhibitor of

the replication of both HSV and vaccinia virus in cell
cultures

(181, 182) and in experimental deep herpes

keratitis in rabbits

(184).

Clinical investigations

33-

of 5-ethyl-2 ’-deoxyuridine indicate a positive therapeutic
effect in the therapy of herpetic keratitis

(185,

186).

5- Ethyl-2’-deoxyuridine is not as effective as IUdR
or F^TdR,

but its potential as an antiviral agent is

based on its non-mutagenic effect on the studies in
phage and drosophila

(187,

188).

It also has no effect

upon the chromosome morphology of l>uman lymphocytes
and

fibroblasts in culture

(189).

Other 5-alkyl analogs of thymidine such as 5-vinyl-,
5- propyl-,

and 5-allyl-2*-deoxyuridine

have been

synthesized and shown to have antiviral activity against
both HSV-1 and HSV-2 in cell cultures

(190).

6-Azauridine

6- Azauridine is a broad spectrum antiviral agent
effective against a variety of RNA and DNA viruses in
vitro.

The inhibition of HSV replication by 6-azauridine

has been reported by several investigators

(191,

192).

6- Azauridine is similarly effective against herpes
simplex keratitis in rabbits

(191) and herpes simplex

stromal infection of the eye in humans

(193),

However,

the clinical applicability of 6-azauridine in the
treatment of HSV infection is severely limited by its
low potency and its toxicity.

Reported cases of serious

34-
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central nervous system disturbance have been associated
with the use of 6-azauridine

(194).

In addition,

this

antiviral agent is both immunosuppressive and teratogenic.

1-Beta-D-Ribofuranosy1-1.2,4.-Triazole-3-Carboxamide

1-Beta-D-ribofuranosyl-1,2,4,-triazole-3-carboxamide
(Virazole,

Ribavirin)

is a broad spectrum antiviral agent

active against RNA and DBA viruses in vitro and in vivo
(195,

196).

It has been shown to be effective in the

treatment of experimental herpes and vaccinia keratitis
in rabbits

(197) .

The potential of this broad spectrum compound
in the treatment of clinical diseases is limited by
two factors.

Firstly,

it must be administered as a

prophylactic agent in order to exhibit its effectiveness
as an antiviral agent.

Secondly,

been observed with this agent

teratogenesis has

(165).

Photodynamic Inactivation of HSV Infections

Another investigative approach to the treatment of

HSV infections is that of photodynamic inactivation of
HSV.

The experimental works of Wallis and Kelnick

revealed the in vitro inactivation of HSV by exposure
to heterotricyclic dyes and light
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(198,

199).

The heterotricycle acridine and phenazine dyes are
photoactive compounds capable of absorbing light energy
and participating

in photo-oxidation

phenazine compound neutral
in the photodynamic
infections
potential

red was the first

in humans

(200),

has greater effectiveness

(201),

of viruses

it has

been

is

photodynamic

dependent upon the dye
and pH.

The progeny virus

becomes sensitive to light when grown in cells
treated with heterotricyclic dyes
incorporated into the virus DNA

(203),

The virus

energy to produce an oxidation reaction,

the subsequent breaks
In this manner,

resulting

in the- base sequence,

in the DMA of

is

sufficient

the virus

in

and
(204) .

HSV can be made photosensitive by the

incorporation of a heterotricyclic dye into its
that subsequent exposure to visible light

HSV noninfectious,
The use of

pre¬

(202) . The dye is

inactivated when the dye-DMA complex absorbs

gaps

which

in photosensitizing viruses

temperature,

the loss of guanine,

red’s

an acridine dye,

(199), The effectiveness of

concentration,

dye used

Because of neutral

as a contact allergen

inactivation

The

inactivation of herpes simplex skin

replaced by the use of proflavin,

in vitro

reactions.

DMA so

renders the

(198) ,

photodynamic dyes has been

applied in the treatment of

experimental

36-
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successfully

herpes simplex

keratitis

in rabbits

effective than that of

(205,

206,

IUdR

(206).

reported the effectiveness of
of eczema herpeticum,
tions

in humans

(200,

207),

but

inactivation

and genital

208-216).

is less

Other studies have

photodynamic

orolabial

it

However,

HSV infec¬

other investi¬

gators have reported opposite results which failed to
demonstrate antiviral activity
genital
(217,

HSV

218,

infection and in

in the treatment

of

recurrent HSV infection

219).

There are hazards associated with the use of
photodynamic dyes,and its clinical application remains
rather controversial.
have been shown to
mammalian

cells

properties

inactivated HSV

induce neoplastic transformation of

in vitro

in vivo

Interferon and

The photodynamic

(200)

which have oncogenic

(221).

Interferon

Inducers

Interferon and interferon inducers are of great
biologic

interest as potential

agents.

At the present time,

clinically useful
of viral

broad spectrum antiviral
they have not proved to be

in the prophylaxis or the treatment

infections.

of human interferon

Studies of the topical application
in the treatment

are rather disappointing

(222) .
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of herpetic keratitis

Studies aimed at the prevention
herpetic

infections

in

recurrent ocular

humans with topical

interferon were also therapeutic
Another disadvantage
or local

of

failures

in using

leucocyte
(223) ,

induced,

systemic,

interferon is the capability of the host cells

to be stimulated only for a limited period of
(6 to 10 weeks),

after which they need a

rest

time
period of

3 weeks before induction could be started again
The use of

inducers of

double-stranded RbA's
propanediamin.es are

interferon such as
(poly I--ploy C)

just as

(224,

polymers of

and substituted

disappointing since they

are usually accompanied by considerable toxicity
227,

228,

225) .

(226,

229) .

5~Iodo~5*-Amino-2 *,5 *-Dideoxyuridine

From the previous
analogues,
inducers,

discussion of antiviral nucleoside

photodynamic dyes,
it

interferon and interferon

is evident that none of these agents

constitute an ideal

chemotherapeutic agent against

HSV infection in humans.

The most worrisome characteris¬

tics of the nucleoside analogues are their low solubility
and their toxicity to the uninfected host cells.

These

toxic side effects are presumably due to the incorpora¬
tion of the drugs

into the nucleic acids of the uninfected

38-
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.

cells,
of

resulting

in cytotoxicity and the potential

inducing mutagenesis

an antiviral
acids of

agent which is

only the virus

cells will

and carcinogenesis.
incorporated

Hence,

into the nucleic

infected cells and not the uninfected

provide a major advance toward minimizing the

toxicities commonly associated with the current antiviral
therapy.
S-Iodo-5'-amino-2*,5'-dideoxyuridine or AIU is
5'-amino analog of

lUdR which was originally synthesized

in the laboratory of W.H.
1974
its

(230).

the

The initial

Prusoff at

Yale University in

studies of AIU demonstrated

in vitro capability as a potent inhibitor of HSV-1.

AIU was

shown to be more potent than Ara-A but less

potent than lUdR,

F^TdS,

The most significant

or Ara-C on a molar basis.

finding was the absence of any

cytotoxicity associated with the use of AIU,

as opposed

to the toxicity observed with similar concentrations
of

lUdR,

F^TdR,

with Ara-A,
peutic

Ara-A,

and Ara-C

(2).

When compared

a nucleoside analog noted for its high thera¬

index,

Ara-A was

found to have significant

toxicity at concentration that produced less anti¬
viral activity than AIU.
AIU*s lack of cytotoxicity was
in the following cell
sarcoma 180,

further demonstrated

lines examined in culture:

Erhlich ascites,

BHK-21
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murine

(hamster kidney).

HeLa,

secondary chicken embryonic

L cells (231).

In addition,

detectable morphological
normal

rate of

cells

(2).

fibroblasts,

AIU at

200

jiM produced no

changes nor inhibited the

DNA and RHA synthesis of uninfected Vero

In vivo studies with the intraperitoneal
tion of AIU in newborn and 8
also

A-9 and

administra¬

day old suckling mice

produced no growth retardation nor teratogenic

effects.

In contrast,

IUdR administered intraperitoneally

produced growth retardation,
evidence of cataract,
lesions,

cortical

retinal

lesions,

organ development

as well

as histopathological

dysplasia,

cerebellar

and general retardation

of

(232).

A study of AIU in the treatment of
herpetic keratitis

experimental

in rabbits established

its therapeutic effectiveness on experimental herpetic
keratitis
than

IUdR,

in

rabbits

viral

(233).

potent

recovery studies showed AIU and IUdR

to be equally effective
HSV-1

Although AIU is less

in reducing the titer of

in the treated tissues.
Given the experimental

data documenting the thera¬

peutic effectiveness of AIU on HSV-1 keratitis
and the absence of cytotoxicity,

in

rabbits

AIU appears to be a

promising agent which should be tested in the treatment
of other forms of HSV-1

infections.
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Cutaneous herpes
stantial morbidity in
and can

sometimes

infections are the cause of

sub¬

the otherwise healthy population

result

in the mortality of newborns

and patients with diminished

immunologic competence.

Disseminated or severely localized herpes simplex
infections are life-threatening complications

in

the

patients with hematologic malignancies or in patients
with immunosuppressive therapy following
plantation,

severe burns,

malnutrition,

renal trans¬
and

immune defi¬

ciency syndromes such as the Wiskott-Aldrich syndrome
(92,

234,

235,

HSV infections

236).

The occurrence of

is expected to

life-threatening

increase,

due to the

current treatment of malignancies with chemotherapeutic
agents having significant
Hence,

there will

be an

immunosuppressive action.

increasing need for an effective

antiherpetic agent having minimum cytotoxicity for the
topical

or systemic treatment and prophylaxis of cutaneous

and oral herpes

simplex lesions

in these patients.

Given the preliminary studies of AIU,
a

promising agent which should be

it appears

investigated

for the

treatment of cutaneous herpes simplex infection.
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to be

V.

I.

Materials and Methods

Drugs.
A.

IUdR was obtained from Sigma
St.

B.

Lousi,

in the laboratory of W.H.

Professor of

Iharmacology,

as described by Lin,
C.

II.

et al,

1976

form at

Preparation of

10

Fiore,

Hospital,
5 gm.

(w/w).

the drugs.

Department of

Boston,

form by

the Massachusetts

General

MA.

IUdR was mixed into petrolatum base to

make an
The

in

Director of the Pharmacy Research and

Development

A.

Company

percent concentration

The drugs were prepared into ointment
Al

Yale University,

(1).

Ara-AMF was provided by Fark-Davis
ointment

Company,

MO.

AIU was synthesized
Frusoff,

Chemical

IUdR ointment at 0.5% concentration

IUdR ointment was then

syringes

(1 ml.)

to yield a

0.5% IUdR ointment.
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(w/w).

loaded into 70 tuberculin
total

of 70 ml.

of

B.

9 gm.

AIU was mixed into a

make an AIU ointment at
The AiU ointment was
syringes

(1 ml.)

petrolatum base to

10% concentration

then loaded into 70

to yield a

total

of

(w/w).
tuberculin

70 ml.

of

10% AIU ointment.

C. 15 tubes of 3.55 gm. of Ara-AMP ointment at 10%
concentration
Company.
50

(w/w)

was provided by tark-Davis

The Ara-AMP ointment was

tuberculin syringes

loaded

to yield 50 ml.

into

of Ara-AMP

ointment.
D.

of

10%

(w/w) lactose ointment, as prepared by

Fiore,

was

loaded

70 ml.
A1

into 70 tuberculin syringes.

The tuberculin syringes containing the drugs were
coded by a member of

the laboratory who was not

involved in the daily examination and the grading
of

the HSV cutaneous lesions of

The drugs were labeled as

the guinea

drug A,

drug code was not known to the

B,

C,

pigs.

and D.

The

investigators until

the experiment had been completed.

III.

Guinea

A total

Iiqs.

of

were used,

21

adult male Hartley strain guinea

each weighing between

pigs

300 and 500 grams.

The guinea pigs within the same treatment group
were kept

in the same cage.
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Daily feeding of

the

guinea pigs and maintenance care of

the cages were

provided.

IV.

Herpes

Simplex Virus

- Type 1

The HSV-1 was provided by E-ravin Bhatt at Yale
University.

The HSV-1

NIH strain No.
10

TCID^g/ml.

until

V.

11124,

used in the experiment was
contained

The virus

the time of

in a

solution of

solution was kept

frozen

inoculation.

Procedures

The hair on the dorsum of

the guinea

pigs was

using electric clippers.

A chemical

depilatory

(Nair,

Carter Products,

moistened,

N.Y.)

shaved area of

for 10 minutes.

was applied on the

the guinea

The shaved area was

with warm water to

pig dorsum
then rinsed

remove the depilatory.

shaved area of the guinea pig dorsum was
with soft towels.
pens,

Using indelible

The
dried

ink

the shaved dorsum was marked into a grid of

six squares,

The guinea
of

shaved

each square measuring

2 cm.

x 2 cm.

pigs were then anesthesized using 0.4 ml.

sodium pentobarbital

injected intraperitoneally.

While the guinea pigs were under the sodium pento¬
barbital anesthesia,

0.02 ml.
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of

thawed HSV-1

solution

7

at

10

TCID^q/itiI .

was applied topically to the surface

of

the guinea pig at each square of

the grid,

tuberculin syringe to measure the HSV-1
HSV-1 was

then inoculated

using a

solution.

intradermally with a

spring-

loaded vaccination

instrument

(Sterneedle,

Ian Ray

sion,

Englewood,

lew Jersey),

10

Ormond Drug,

each square.
produced a

The spring-loaded vaccination

ring of

The

times

Divi¬
in

instrument

six inoculation site to a

depth of

0.75 mm.
After the intradermal

inoculation of

the HSV-1,

the

guinea pigs were randomly distributed into four treatment
groups as

follows:
Drug A- -five guinea
Drug

B- -five guinea pigs

Drug C- -six

guinea

pigs

Drug

guinea

pigs

D-

The drug treatment was begun
inoculation of

pigs

HSV-1.

0.1 ml.

of

immediately after the
ointment from the

tuberculin syringes was applied topically to each square
of

the grid and was gently rubbed onto the entire surface

of the square.

After the drug application,

the guinea

pigs were returned to their respective cages.
treatment schedule was

repeated every 8 hours

The
for 6

consecutive days.
During the morning treatment sessions,
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two investigators

independently grade the lesions on each guinea
the treatment was begun.

These two

not know the drug code until

pig before

investigators

the termination of

did

the

experiment.
Each guinea pig was examined daily for 11
the two investigators,
dermal
HSV-1

inoculation
lesions

criteria
1.

starting 1

of HSV-1.

days

day after the

by

intra-

The development of

the

in each square was evaluated by the

of:

Erythema*

graded on a scale of 0

to 4,

based on

the intensity and the area of erythema.
0 = no erythema
1

= slight erythema:involving a small
area

2 = moderate erythema:either greater
v

intensity of

erythema

or extension of
found in

than

in

(1)

the area of erythema

(1)

3 = moderately severe erythemasgreater
intensity of erythema
and/or extension of
erythema

found in

than

in

the area of

(2)

4 = severe erythemajgreatest

intensity

of erythema compared to that
in

(1),

(2),

and

(3).

erythema greater than

46-
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(2)

found

The area of
in

(3)

.

2.

Vesicles

s

graded on a

scale of

0,

1,

2,

3,

. ..;

corresponding to the number of vesicles
found in each square.

The guinea

pig hair regrew within

5 days,

necessita¬

ting another application of chemical

depilatory on day

on the dorsum of

described previously.

Histopathologic

One guinea

the guinea

pig

in each treatment group was

pathologic studies.
disposable 3 mm.

the skin lesions

for histo¬

diameter Chester Baker Skin biopsy Punch.
then preserved

in a

formalde¬

The histology slides were prepared by the

Fathology Laboratory at the Massachusetts
infirmary,

selected

The lesion was biopsied, by Using a

biopsied specimen was

hyde solution.

as

studies

on day 6 for the biopsy of

The

pigs,

5

Boston,

MA.
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Eye and Ear

VI.

In this controlled,
HSV-1

Results

double-masked experiment,

inoculated guinea pigs were

into four treatment groups.

randomly distributed

Each guinea

daily for the development of the HSV-1

pig was examined

lesions.

cutaneous lesions were graded for 10 days by two
investigators,

the

The HSV-1
independent

according to the criteria of

(1)

erythema

(2)

vesicles

in the manner described in the procedures.
Each of

the four treatment groups had five guinea

pigs within each group
guinea pigs,

but one of

sustained during one of
experiment).
and 6 HSV-1

(Notes

one of the groups had 6

the guinea

pigs died from trauma

the procedures on day 5 of

With 5 guinea pigs

the

per treatment group

inoculation sites per guinea pig,

there were

30 lesion sites which were examined daily in each treatment
group.
Since each lesion was
the two investigators,

independently evaluated by

60 lesion

-48-

scores were recorded

for each criterion per treatment group per day.
the 4 treatment groups
240

in the experiment,

a

Given

total

of

lesion scores were recorded per criterion per day

for all 4 treatment groups.
evaluated,

a

total

For the two criteria

of 480 lesion scores were recorded per

day for the 4 treatment groups.
days,

to be

there were 4,800

Over the course of 10

lesion scores

recorded for the 4

treatment groups.
In order to evaluate the efficacy of
treatments on HSV-1

cutaneous

lesions

it was necessary to simplify the 4,800
consolidating this data

in

the 4 drug

in the guinea

lesion scores by

the form of mean lesion

for each criterion per treatment group per day.
scores of

the HSV-1 cutaneous

are tabulated in
in Table 3

Table 1

pigs,

lesions of

score

The mean

the guinea

pigs

for the mean erythema score and

for the mean vesicle score.

In this controlled,

double-masked experiment on the

efficacy of AIU treatment on cutaneous
guinea pigs,

HSV-1

lesions

in

none of the guinea pigs developed zosteriform

distribution of

the HSV-1

neurologic signs such as
The HSV-1 cutaneous

lesions nor manifested any
limb paralysis or encephalitis.

lesions which developed progressed

from an area of erythema

to vesicle formation,

crusting of the vesicles and finally healing of
by day 11.
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then
the lesions

From the raw data,

as well

mean scores of erythema

shown

that one day after the HSV-1

as

in

Table 1,

inoculation,

sites became slightly erythematous
£l.68).

By days

5 and 6,

all

4

the maximum mean erythema score
day post HSV-1

inoculation,

ressively declined until
on the 11th day
erythematous

it
the

is evident
inoculated

(mean erythema score

treatment groups had attained
(*£2.27).

After the 6th

the mean erythema

scores

lesions at 3

See Plate 1,

depicting

3

inoculated sites on the 3rd day

1).

Although all

4 treatment groups demonstrated similar

trends

in the development of

sites,

the AIU and the Ara-AKF treatment groups

somewhat

prog¬

the termination of the experiment

(<0.15).

(erythema score =

from the calculated

in that an

initial

rise of

scores occurred on

day

2 and 3.

followed by a

This was

1,

erythema at the

erythema

scores on days

scores.

See Figure 1

inoculated
differed

the mean erythema

which then subsided by days
second rise of

the mean

5 and 6 to produce their maximum

for the graph of

the mean erythema

score for the 4 treatment groups.
Even though the trends
erythema were similar
actual values of

for the development of

in all 4 treatment groups,

the mean erythema

each of the treatment groups.
the cumulative mean erythema

This

scores

differed in

is exemplified by

scores of

-50-

the

the four treatment

-

groups

(see Table

mean erythema

2).

scores shown

the lactose group
erythema

From the graph of
in

(control)

score than the other 3

scores are

:

Ara-AMF

The data of

groups.

discrete vesicles,

Plate
of

the

the cumulative mean erythema

began on day

as tabulated

showed that the
3

in all

4 treatment

initially develped as small,

surrounded by an erythematous

base

The vesicles gradually enlarged in size,
ju^posed vesicles coalescing to form

confluent vesicular lesions

3).

In

by the 6th day

The fully developed lesions,

(see

which consisted

discrete and coalescing vesicles on an erythematous

base,

began to show signs of crusting by day 7

The crusting of

the lesions

in all 4 treatment groups
all

treatment groups.

in Figure 3,

These vesicles

with some of

is clear that

the mean vesicular scores,

of vesicles

(see Plate 2).

it

IUdR <AIU^ Lactose.

in Table 3 and graphed
development

2,

had a greater cumulative mean

increasing order of magnitude,

larger,

Figure

the cumulative

(see Plate 4).

progressed from day 7

(see plate

5).

the vesicular lesions had healed as

to day 10

By the 11th day,
shown

in Plate 6

(mean vesicular score = 0.00).
The trend observed in the mean vesicular scores
the 4 treatment groups differed somewhat

among

the groups

in terms of the time the maximum number of vesicles
(see Figure 3).

That

is,

for

developed

the maximum number of vesicles
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developed on the 4th day for AIU,
on the 7th day for Lactose,

on the

lUdR,

and on the 8th day for Ara-AMF.

Although the 4 treatment groups had all
healed by the 11th day,

6th day for

their vesicles

some treatments accelerated and

others delayed the onset of

the development of the

maximum number of vesicles by a

few days.

The cumulative mean vesicular scores

for the 4

treatment groups are similar to the cumulative mean
erythema

scores

treated group

(see Figure 4).

(control)

vesicular score,

as compared to AIU,

the 4

increasing value:

Statistical

Ara-AMF,

and

The cumulative mean

treatment groups are in order

Ara-AMF< IUdR< AIU< Lactose.

analysis:

The guinea pigs

in the lactose treatment group

provided the control group for this experiment.
the data on the mean erythema
score,

it

is evident that

2

in guinea

pigs.

From

score and the mean vesicular

the lactose treatment was not

as effective as the other 3 treatments
lesions

IUdR.

the cumulative mean vesicular

scores are tabulated in Table 4.
vesicular scores of

the lactose

had the highest cumulative mean

The calculated values of

of

Once again,

This

is

for HSV-1

best depicted

cutaneous

in Figures

and 4 where their respective cumulative scores are

graphed,

showing the lactose group having the greatest

-52-

score in both criteria.

The differences between the control

group and the other 3 treatment groups are significant:

Mean Erythema Score:
1.

Lactose and AIU:

minimum modifi ed%*17.9112

2.

Lactose and IUdR:

3.

Lactose and Ara-AMP:

min.

mod.%1

min.

mod.'Xt

(p< 0.001)

77.0324

(p< 0.001)

109.9078

(p^ 0.001)

Mean Vesicular Score:
-X

minimum modified8.4237

1.

Lactose and AIU:

2.

Lactose and

3.

Lacotse and Ara-AMF:

This statistical

IUdR:

analysis

min.

mod.OC*

min.

mod/X*”

demonstrates a

69.5720

(p< 0.001)

119.9783

(p< 0.001)

significant

treatment effect of AIU,

IUdR,

of erythema and vesicles

in the experimentally

cutaneous HSV-1

and Ara-AMP on the development

lesions of guinea

■53-

(p< 0.004)

pigs.

induced

.

VII.

There
clinical

Discussion

is no satisfactory agent available for the

treatment of cutaneous herpes

in humans

simplex infections

in the United States at this time.

agents with therapeutic effectiveness
experimentally hav? thus
mutagenic,

Antiviral

that are available

far proved to be either teratogenic,

or too cytotoxic to be used clinically.

evident that a critical need exists

It

is

for a clinically effective

agent against cutaneous herpes simplex infection which also
does not produce intolerable toxic effects.
Cutaneous herpes simplex infections have been studied
in the past,
routes.

using a variety of

species and inoculation

Studies of cutaneous herpes simplex infections

have been reported using the inoculation of
ear of mice

(237),

the skin of

rabbits

into the skin of guinea pigs
(239,

with 1% hyaluronidase
pigs

(242),

of

rats

240),

(241),

into the skin of

(244,

245,

(238),

into

rabbits

into the footpad of guinea

into the skin of mice

of hairless mice

HSV info the

246,

(248).
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(243),
247),

into the skin

and into the skin

Most of

these models have not been totally satis¬

factory since they failed to produce localized,
lesions of HSV of

the skin which simulate the course of

the disease in humans.
these models
herpes

has

Another problem encountered in

been the high incidence of generalized

simplex infection,

paralysis,
of HSV.

recurrent

leading to herpes encephalitis,

and death following the intradermal

inoculation

Others have reported the development of segmental,

zosteriform

distribution of

with evidence of virus

the herpes simplex vesicles,

spread along the peripheral nerves

(247).
The inoculation
by Hubler,
(238).

et al., in

This

technique of

intradermal

1974 has none of

the above deficiencies

inoculation technique was successfully used

in this study to inoculate the guinea
HSV-1.

HSV described

None of the guinea pigs

any signs of generalized herpes
encephalitis,

paralysis,

the cutaneous

lesions.

pigs with intradermal

in this study developed
simplex infection,

or zosteriform distribution of
The progression of

the herpes

lesions simulated the course of cutaneous herpes
found in humans.

herpes

Given this experimental

cutaneous herpes simplex lesions,

model

lesions
for

we were able to test

the efficacy of AIU for the therapy of herpes simplex
cutaneous

infection

in guinea pigs.

AIU is a thymidine analogue differing

from IUdR

by the substitution of an amino group for 5*

55-

hydroxyl.

AIU has been shown in previous studies to inhibit the in
vitro replication of HSV-1

(2), as well as to be efficacious

in the treatement of herpes simplex keratitis in rabbits
(240).
The present controlled,

double-masked experiment

demonstrates a significant treatment effect of AIU in
the therapy of cutaneous herpes simplex infection in
guinea pigs.

The critical difference between AIU and the

other antiviral nucleoside analogues is the absence of any
detectable teratogenic or cytotoxic effects associated with
the use of AIU (231,

232).

This finding seems to suggest

a virus-specified site of inhibition as the basis of its
antiviral action.

The supporting evidence for this theory

comes from the findings listed below:

1.

The critical time of action of AIU appears to be
during the replication of HSV within the host cell.
The pre-incubation of HSV with AIU prior to in
vitro infection or the presence of AIU in the media
during the absorption process did not inhibit the
production of virus.

Only when AIU was added 4 to

6 hours after infection was there a marked reduction
in the yield of progeny virus

2.

(2).

AIU has no inhibitory effect on the rate of RNA
and protein synthesis in either the HSV-infected
Vero cells or the uninfected Vero cells.

56

More

.

importantly, AIU does inhibit the uptake of labeled
thymidine into the ENA of HSV-infected Vero cells,
but not in the uninfected Vero cells

(2).

3. AIU is metabolized in vitro by only HSV infected cells.
After its conversion to the 5*-triphosphate,

it is

incorporated into both viral and cellular DNA of the
infected cells.

AIU appears to be selectively phos-

phorylated in HSV-infected cells, mediated by the
HSV specified thymidine kinase (249).
4. HSV mutants defective in thymidine kinase are totally
resistant to AIU.

The selective phosphorylation of AIU and its incorpora¬
tion into the DNA of the infected cell could certainly account
for its specific antiviral activity and its absence of host
toxicity.

This important characteristic of AIU differentiates

it from all the other antiviral agents as a potential drug
in the treatment of HSV infections in humans.
This study has shown the effectiveness of AIU on one
type of HSV-1 infection, that of cutaneous HSV-1 infection
in guinea pigs.

Further investigations on the efficacy of

AIU on other forms of HSV infections will be worthwhile,
particularly those HSV infections presenting as life-threat¬
ening disseminated infections of the newborn and the iramunosuppressed patients.

The possible role of AIU in the treat¬

ment of recurrent HSV infection, herpes encephalitis, and
genital herpes would also merit further investigation.

-57-

VIII.

1.

Significant

Summary

treatment effect of AIU on experimentally

induced herpes simplex

virus

type 1

cutaneous lesions in

guinea pigs was demonstrated.

2.

Significant treatment effect of

IUdR and Ara-AMP

on experimentally induced herpes

simplex virus

cutaneous lesions

3.

in guinea

pigs was also demonstrated.

The potency of

thesethree drugs,

potency

follows:

as

AIU < IUdR < Ara-AMP .

-58-

type 1

in order of

increasing
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TABLE

1

ERYTHEMA - MEAN LESION SCORE /DAY

Days after
Inoculation

AIU

Ara-AMP

IUdR

Lactose

1

1.68

0.85

0.49

0.43

2

0.75

0.50

0.70

0.76

3

1.04

0.33

0.91

1.05

4

1.10

0.86

1.16

1.42

5

2.20

0.95

1.21

2.25

6

1.46

1.76

1.67

2.27

7

0.92

0.84

1.22

2.10

8

0.77

0.72

0.73

1.33

10

0.33

0.43

0.05

0.72

11.

0.03

0.15

0.00

0.07
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Inoculation
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2.10
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4

4.57

2.53
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3 . 66

5

6.77

3.48

4.46

5 .91

6

8.23

5.24

6.12

8 .18

7

9.15

6.08

7.35

10 .28

8

9.92

6.80

8.08

11 . 61

10

10.25

7.23

8.13

12 .33

11

10.28

7.38

8.13

12 .40
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3

VESICLES - MEAN LESION SCORE/DAY

Days After
Inoculation
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0.00
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2.35
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10

1.34

1.57
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11

0.00

0.00

0.00

0.00
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TABLE

4

VESICLES - CUMULATIVE MEAN VESICULAR SCORE

Days After
Inoculation

AIU

Ara-AMF

lUdR

Lactose

1

0.00

0.00
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0.00

2

0.00

0.00
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0.00

3
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0.12

1.03
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3.08

5
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6.00

6

7.88
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9.56

7
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3.06

7.84

13.44

8

12.57

4.78

9.01

15.69

10

13.91

6.35

9.58
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11

13.91

6.35

9.58

17.42
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Plate 1

i Erythematous lesions (erythema score = 1)
at 3 inoculated sites of guinea pig
skin on the 3rd day after HSV-1 inoculation.

-90-

Plate 2

i Small, discrete vesicles surrounded by an
erythematous base found at the inoculated
site of guinea pig skin 4 days post HSV-1
inoculation.

-91-

Plate 3

* Juxtaposed vesicles have coalesced to
form larger, confluent vesicular lesions
at 2 inoculation sites of guinea pig
skin at 6 days post HSV-1 inoculation.

92

Plate 4

* The vesicular lesions of guinea pig skin
demonstrate the initial signs of crusting,
as shown here at 7 days post HSV-1
inoculation.

-93-

Plate 5

« Crusting of the HSV-1 lesions found in
the guinea pig skin 10 days after HSV-1
inoculation.

94

Plate 6

: On the 11th day post HSV-1 inoculation,
the lesions have completely healed at
the HSV-1 inoculated sites of the
guinea pig skin.

95

Plate 7 i Histology of guinea pig skin infected
with herpes simplex virus type 1 at 6
days after virus inoculation, demonstrat¬
ing the ballooning degeneration of epidermal
cells and eosinophilic viral inclusion
bodies (H.E.Stain)•

-96-

Plate 8 i Histology of guinea pig skin infected
with herpes simplex virus type 1 at 6
days after virus inoculation, demon¬
strating the ballooning degeneration
of epidermal cells and the red viral
inclusion bodies (Page-Green Stain).
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